Stascheit, Frauke http://orcid.org/0000-0001-5306-7880
Grittner, Ulrike
Hoffmann, Sarah
Mergenthaler, Philipp
Schroeter, Michael
Ruck, Tobias
Pawlitzki, Mark
Blaes, Franz
Kaiser, Julia
Schara, Ulrike
Della-Marina, Adela
Thieme, Andrea
Hagenacker, Tim
Jacobi, Christian
Berger, Benjamin
Urban, Peter P.
Knop, Karl Christian
Schalke, Berthold
Lee, De-Hyung
Kalischewski, Petra
Wiendl, Heinz
Meisel, Andreas
Clinical trials referenced in this document:
Documents that mention this clinical trial
Risk and course of COVID-19 in immunosuppressed patients with myasthenia gravis
https://doi.org/10.1007/s00415-022-11389-0
Funding for this research was provided by:
Bundesministerium für Bildung und Forschung (NUM-COVID 19 – Organo-Strat 01KX2021)
German myasthenia gravis Society
Alexion Pharmaceuticals
Einstein Stiftung Berlin (16GW0191)
Charité - Universitätsmedizin Berlin
Article History
Received: 27 July 2022
Revised: 16 September 2022
Accepted: 17 September 2022
First Online: 27 September 2022
Declarations
:
: F. Stascheit received speaker honoraria from Alexion. U. Grittner reports no conflict of interest, S. Hoffmann received speaker honoraria from Alexion. P. Mergenthaler receives funding from the Einstein Foundation Berlin, and is supported by grants from the Bundesministerium für Bildung und Forschung, the Volkswagen Foundation, and the Else Kröner Fresenius Stiftung, and is on the board of HealthNextGen Inc. and has equity interest in the company. M. Schroeter reports speaker honoraria from Argenx, Bayer, Biogen, Datamed, Grifols, Merck, Roche, Sanofi. He received consulting fees from Alexion, Biogen, Argenx/Efran MG, Gilead, and Roche. T. Ruck reports grants from German Ministry of Education, Science, Research and Technology, grants and personal fees from Sanofi-Genzyme, Novartis and Alexion; personal fees from Abbott, argenx, Biogen, Bristol-Myers Squibb, Roche and Teva; personal fees and nonfinancial support from Merck Serono, outside the submitted work. F. Blaes received speaker honoraria from UCB, Argenx, Alexion and Grifols. J. Kaiser reports no conflicts of interests. U. Schara received speaker honoria from Alexion and Biogen. A. D. Marina reports no conflicts of interests. A. Thieme reports no conflicts of interests. T. Hagenacker reports speaker honoraria from Alexion, argenx and Hormosan, Biogen, Roche Sanofi Genzyme and Novartis Gene Therapies. He received consulting fees from Biogen, Roche, Sanofi Genzyme, Alexion, argenx, Hormsosan and Alnylam and research support from Sanofi Genzyme, Roche, Biogen and Novartis. C. Jacobi reports speaker honoraria from Alexion, CSL Behring, TEVA and Sanofi Genzyme. He received consulting fees from Alexion, Roche, Merck Serono and Novartis. P. P. Urban received speaker honoraria from Alexion. B. Berger received travel grants and/or training expenses from Bayer Vital GmbH, Ipsen Pharma GmbH, Norvartis, Biogen GmbH and Genzyme, as well as lecture fees from Ipsen Pharma GmbH, Alexion Pharma GmbH, Merck, Sanofi Genzyme and Roche. K. C. Knop received speaker honoraria from Alexion, Bayer, Biogen, Grifols, Hormosan, Novartis, Sanofi Genzyme, Roche and consulting fees from Hormosan, Merck, Sanofi Genzyme and Sarepta. B. Schalke received consulting fees from argnx. D.J. Lee received speaking honoria from Alexion, Anylam, Biogen, Janssen, Merck, Novartis, Roche and Sanofi. P. Kalischewski received speaker honoraria, consulting fees and NIS from Biogen, Sanofi, Teva, Merck, Roche, Novartis and Biogen. M. Pawlitzki received speaker honoraria and travel/accommodation/meeting expenses from Novartis. H. Wiendl is acting as a paid consultant for Abbvie, Actelion, Biogen, IGES, Johnson & Johnson, Novartis, Roche, Sanofi-Aventis, and the Swiss Multiple Sclerosis Society. His research is funded by the German Ministry for Education and Research (BMBF), Deutsche Forschungsgemeinschaft (DFG), Else Kröner Fresenius Foundation, Fresenius Foundation, the European Union, Hertie Foundation, NRW Ministry of Education and Research, Interdisciplinary Center for Clinical Studies (IZKF) Muenster and RE Children’s Foundation, Biogen, GlaxoSmithKline GmbH, Roche Pharma AG, Sanofi-Genzyme. A. Meisel received speaker honoraria, consulting fees or financial research support from Alexion, argnx, Grifols, Hormosan, Janssen, Octapharmam UCB and Vitaccess for consulting services and financial research support from Octapharma and Alexion. He serves as chairman of the medical advisory board of the German Myasthenia Gravis Society.
: The study was conducted in accordance to the Declaration of Helsinki and the STROBE reporting guidelines and was registered at the WHO-licensed German clinical trial registry (DRKS00024099). The study was approved by the ethics committee of the Charité-Universitätsmedizin Berlin (EA1/025/11).
: Informed consent was obtained from all individual participants included in the study.
: All authors have approved the manuscript for submission; accordingly, the manuscript conforms to the journal’s policies. The authors take full responsibility for the data, the analyses and interpretation, and the conduct of the research. They have full access to all data, and the right to publish any and all data separate and apart from the guidance of any sponsor.